Omni-stat Celox

PreclinicalSmall molecule

CCardiochirurgia E.H.

Omni-stat Celox is one of 20 small molecule programs targeting Cardiac Surgery. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiac SurgeryTerminated

Cardiac SurgeryPreclinical

Terminated

Competition

Competitive Landscape

30 competitors in Cardiac Surgery

#DrugCompanyPhaseTrials

Farxiga

AstraZeneca

Approved

2 2

Vancocin

HHikma Pharmaceuticals LLC

Approved

5 3

Ancef

BBaxter Healthcare Corporation

Approved

3 4

Pitressin

AAultman Health Foundation

Approved

2 5

Neo-Synephrine

EExela Pharma Sciences, LLC.

Approved

1 6

Naropin

FFresenius Kabi USA, LLC

Approved

1 7

Dolophine

HHikma Pharmaceuticals LLC

Phase 3

2 8

Bridion

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

2 9

Oruvail

WWyeth-Lederle Vaccines

Phase 3

1 10

Acanya

Pfizer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cardiac Surgery1 trial

Blood Sparing Strategies: Omni-stat Routinary Use in Cardiac Surgery. A Prospective Randomized Study.

Terminated·CCardiochirurgia E.H.·N/A·NCT01008436·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Omni-stat Celox. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Omni-stat Celox compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Omni-stat Celox. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cardiochirurgia E.H. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CCardiochirurgia E.H.

Omni-stat Celox

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cardiac Surgery1 trial

References

Drug Info

Quick Facts

Related News